Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2017

View Archived Issues

Biocon launches bevacizumab biosimilar Krabeva in India

Plasmepsins IX and X as promising new dual targets for malaria eradication

Data show encouraging activity with BMS-986205 plus nivolumab in phase I/II study

Researchers describe novel potent peptidic inhibitors of influenza hemagglutinin

Chemo group changes its name to Insud Pharma

Novel IDO-1 inhibitors discovered at GlaxoSmithKline

University of Minnesota patents new monocarboxylate transporter 1/4 inhibitors

Inflection Biosciences and RCSI collaborate to understand mechanisms of resistance in breast cancer

University of Michigan presents histone-lysine N-methyltransferase ASH1L inhibitors

Vanc set to launch INSTI HIV rapid point-of-care test

MA-0217 as a promising new agent for ischemic acute kidney injury

Novel antiparasitic compounds synthesized at Anacor

Jubilant Biosys describes new dual KDM1A/HDAC inhibitors

Pharming submits sBLA for Ruconest for prevention of HAE attacks

AstraZeneca seeks Japanese approval for Tagrisso in first-line EGFR-mutated NSCLC

Genfit contributes to LITMUS European consortium in NAFLD

AstraZeneca and Chinese FIIF to establish joint venture in China

Phase III study finds significant ON time improvement with sublingual apomorphine film

Immungenetics initiates DrainAD phase II study of thiethylperazine for the treatment of AD

VS-605, a novel highly effective phosphate binder

HitGen and Boehringer Ingelheim establish drug discovery research collaboration

Symphogen opens phase I study of Sym-021 in advanced solid tumor malignancies or lymphomas

Phase II results for nesvacumab and aflibercept combination therapy do not warrant progression

New study explores BOLT with BMT in primary immunodeficiency patients with end-stage lung disease

Merck Sharp & Dohme initiates phase I study of MK-7252 in healthy subjects

Japanese approval sought for DE-117 for glaucoma and ocular hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
Jiangsu Nhwa Pharmaceutical patents new κ-opioid receptor antagonists
BioWorld Science
Jiangsu Nhwa Pharmaceutical Co. Ltd. has disclosed κ-opioid receptor antagonists that are potentially useful for the treatment of neurological disorders.